Get started
AbbVie Inc.AbbVie Inc.AbbVie Inc.

AbbVie Inc.

No trades
OverviewFinancialsNewsDocumentsCommunityTechnicalsForecastsSeasonalsOptionsBondsETFs

Chart


Full chart

Key facts today


AbbVie forecasts 2026 adjusted EPS at $14.47, 1.7% above estimates. Q4 CY2025 sales reached $16 billion, a 6% increase, with strong growth in immunology and neuroscience.
UBS has a Neutral rating on AbbVie (ABBV) and cut its price target to $230. Evercore ISI also lowered its target for AbbVie shares to $228.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪383.72 B‬ USD
Dividend yield (indicated)
3.19%
Price to earnings Ratio (TTM)
95.33
Basic EPS (TTM)
—
Net income (FY)
‪4.23 B‬ USD
Revenue (FY)
‪61.16 B‬ USD
Shares float
‪1.77 B‬
Beta (1Y)
0.30

About AbbVie Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Robert A. Michael
Website
abbvie.com
Headquarters
North Chicago
Founded
2011
IPO date
Jan 2, 2013
Identifiers
3
ISIN US00287Y1091
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Check out other big names from the same industry as ABBV.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


A
ACT4218883
Allergan Funding SCS 4.75% 15-MAR-2045
Yield to maturity
7.00%
Maturity date
Mar 15, 2045
A
ACT4176286
Allergan Funding SCS 4.85% 15-JUN-2044
Yield to maturity
6.40%
Maturity date
Jun 15, 2044
A
ACT3910526
Actavis, Inc. 4.625% 01-OCT-2042
Yield to maturity
6.38%
Maturity date
Oct 1, 2042
A
ACT4218882
Allergan Funding SCS 4.55% 15-MAR-2035
Yield to maturity
5.79%
Maturity date
Mar 15, 2035
ABBV5759196
AbbVie Inc. 5.5% 15-MAR-2064
Yield to maturity
5.70%
Maturity date
Mar 15, 2064
ABBV5759195
AbbVie Inc. 5.4% 15-MAR-2054
Yield to maturity
5.62%
Maturity date
Mar 15, 2054
ABBV6009613
AbbVie Inc. 5.6% 15-MAR-2055
Yield to maturity
5.59%
Maturity date
Mar 15, 2055
US287YAW9
AbbVie Inc. 4.45% 14-MAY-2046
Yield to maturity
5.57%
Maturity date
May 14, 2046
ABBV5068387
AbbVie Inc. 4.25% 21-NOV-2049
Yield to maturity
5.56%
Maturity date
Nov 21, 2049
ABBV4693583
AbbVie Inc. 4.875% 14-NOV-2048
Yield to maturity
5.55%
Maturity date
Nov 14, 2048
4ABB
AbbVie Inc. 4.7% 14-MAY-2045
Yield to maturity
5.54%
Maturity date
May 14, 2045

See all ABBV bonds 

ETFs holding the stock


VTI
Vanguard Total Stock Market ETF
Weight
0.61%
Market value
‪12.69 B‬
USD
VOO
Vanguard S&P 500 ETF
Weight
0.69%
Market value
‪10.22 B‬
USD
IVV
iShares Core S&P 500 ETF
Weight
0.65%
Market value
‪4.94 B‬
USD
SPY
State Street SPDR S&P 500 ETF
Weight
0.65%
Market value
‪4.60 B‬
USD
VTV
Vanguard Value ETF
Weight
1.70%
Market value
‪3.72 B‬
USD
XLV
State Street Health Care Select Sector SPDR ETF
Weight
6.80%
Market value
‪2.82 B‬
USD
SCHD
Schwab US Dividend Equity ETF
Weight
3.38%
Market value
‪2.76 B‬
USD
VIG
Vanguard Dividend Appreciation ETF
Weight
1.85%
Market value
‪2.23 B‬
USD
VYM
Vanguard High Dividend Yield Index ETF
Weight
1.92%
Market value
‪1.62 B‬
USD
IWF
iShares Russell 1000 Growth ETF
Weight
1.33%
Market value
‪1.55 B‬
USD
VHT
Vanguard Health Care ETF
Weight
4.94%
Market value
‪1.02 B‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of ABBV is 219.02 USD — it has decreased by −3.79% in the past 24 hours. Watch AbbVie Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange AbbVie Inc. stocks are traded under the ticker ABBV.
ABBV stock has fallen by −2.90% compared to the previous week, the month change is a −4.36% fall, over the last year AbbVie Inc. has showed a 14.96% increase.
We've gathered analysts' opinions on AbbVie Inc. future price: according to them, ABBV price has a max estimate of 328.00 USD and a min estimate of 203.00 USD. Watch ABBV chart and read a more detailed AbbVie Inc. stock forecast: see what analysts think of AbbVie Inc. and suggest that you do with its stocks.
ABBV reached its all-time high on Oct 1, 2025 with the price of 244.81 USD, and its all-time low was 32.51 USD and was reached on Dec 17, 2012. View more price dynamics on ABBV chart.
See other stocks reaching their highest and lowest prices.
ABBV stock is 2.72% volatile and has beta coefficient of 0.30. Track AbbVie Inc. stock price on the chart and check out the list of the most volatile stocks — is AbbVie Inc. there?
Today AbbVie Inc. has the market capitalization of ‪383.72 B‬, it has increased by 0.53% over the last week.
Yes, you can track AbbVie Inc. financials in yearly and quarterly reports right on TradingView.
AbbVie Inc. is going to release the next earnings report on Apr 24, 2026. Keep track of upcoming events with our Earnings Calendar.
ABBV earnings for the last quarter are 2.71 USD per share, whereas the estimation was 2.65 USD resulting in a 2.15% surprise. The estimated earnings for the next quarter are 3.03 USD per share. See more details about AbbVie Inc. earnings.
AbbVie Inc. revenue for the last quarter amounts to ‪16.62 B‬ USD, despite the estimated figure of ‪16.41 B‬ USD. In the next quarter, revenue is expected to reach ‪14.66 B‬ USD.
ABBV net income for the last quarter is ‪1.82 B‬ USD, while the quarter before that showed ‪176.00 M‬ USD of net income which accounts for 931.82% change. Track more AbbVie Inc. financial stats to get the full picture.
Yes, ABBV dividends are paid quarterly. The last dividend per share was 1.73 USD. As of today, Dividend Yield (TTM)% is 3.06%. Tracking AbbVie Inc. dividends might help you take more informed decisions.
AbbVie Inc. dividend yield was 2.91% in 2025, and payout ratio reached 279.00%. The year before the numbers were 3.54% and 263.15% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, ABBV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AbbVie Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AbbVie Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AbbVie Inc. stock shows the buy signal. See more of AbbVie Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.